Author

N. Friedland

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:non-human primate· 2 Research Focus:cell type annotation· 1 Organism:mouse· 1

Frequent Co-Authors

M. Sanyal· 4 shared P. S. Kim· 4 shared J. Do· 3 shared C. Hanson· 2 shared D. B. Volkin· 2 shared M. K. Morris· 2 shared S. B. Joshi· 2 shared Y.-C. Cheng· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

M. Sanyal

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines

O. Kumru, M. Sanyal, N. Friedland, J. Hickey, R. Joshi, P. Weidenbacher, J. Do, Y.-C. Cheng, P. S. Kim, S. B. Joshi, D. B. Volkin

This study develops and compares an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced in two cell lines, showing similar immunogenicity despite differences in glycoforms.

Vaccine · Oct 1, 2023Peer-reviewedImmunology

Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern

P. A. Weidenbacher, N. Friedland, M. Sanyal, M. K. Morris, J. Do, C. Hanson, P. S. Kim

This study evaluates the efficacy of a pan-sarbecovirus vaccine candidate against SARS-CoV-2 variants, finding that omitting strain-specific mutations improves cross-reactive neutralizing antibody responses.

bioRxiv · Jun 27, 2023 · PreprintBiochemistry

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

P. A.- B. Weidenbacher, M. Sanyal, N. Friedland, S. Tang, P. S Arunachalam, M. Hu, O. S. Kumru, M. K. Morris, J. Fontenot, L. Shirreff, J. Do, Y.-C. Cheng, G. Vasudevan, M. B. Feinberg, F. J. Villinger, , P. S. Kim

This paper describes a ferritin-based nanoparticle vaccine, DCFHP-alum, that induces strong, long-lasting neutralizing antibodies against SARS-CoV-2 variants in non-human primates.

bioRxiv · Dec 25, 2022Immunology

HIV-1 neutralization tiers are not relevant for inhibitors targeting the pre-hairpin intermediate

B. N. Bell, T. U. J. Bruun, N. Friedland, P. S. Kim

The paper shows that HIV-1 neutralization tiers do not predict the potency of inhibitors targeting the pre-hairpin intermediate, unlike broadly neutralizing antibodies.

bioRxiv · Oct 6, 2022 · PreprintImmunology

Adaption of a Conventional ELISA to a 96-well ELISA-Array for Measuring the Antibody Responses to Influenza virus proteins, viruses and vaccines

E. Waltari, E. Carabajal, M. Sanyal, N. Friedland, K. M. McCutcheon

The paper adapts conventional ELISA to a 96-well ELISA-Array format for measuring antibody responses to influenza antigens, demonstrating comparable sensitivity and precision.

bioRxiv · Dec 20, 2019Immunology